Abstract
Meeting abstracts HD IL-2 was FDA approved for advanced melanoma, but the data supporting its use dates to the 1990's. The PROCLAIMSM registry ( ) is the largest collection of IL-2 treated patients in the US and provides real-time insights into patient survival and
Highlights
high dose IL-2 (HD IL-2) was FDA approved for advanced melanoma, but the data supporting its use dates to the 1990’s
Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2
Patients were stratified into three groups; HD IL-2 only (n=123), HD IL-2 followed by ipilimumab (IL-2®ipi, n=78), and HD IL-2 followed by PD-1 inhibitors (IL-2®aPD-1, n=35)
Summary
Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2. Michael KK Wong, Michael A Morse, David F McDermott, Joseph I Clark, Howard L Kaufman, Gregory A Daniels, Jessica C Perritt, Hong Hua, Sandra Aung7*. From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
